Firsov A A, Vasilov R G, Vostrov S N, Kononenko O V, Lubenko I Y, Zinner S H
Department of Pharmacokinetics, Centre of Science & Technology LekBioTech, Moscow, Russia.
J Antimicrob Chemother. 1999 Apr;43(4):483-90. doi: 10.1093/jac/43.4.483.
To compare the pharmacodynamics of trovafloxacin and ciprofloxacin, three clinical isolates of Staphylococcus aureus with different MICs (0.03, 0.15, 0.6 and 0.1, 0.25, 1.25 mg/L, respectively) were exposed to decreasing concentrations of the quinolones according to their half-lives of 9.25 and 4 h, respectively. With each organism, single doses of trovafloxacin and twice-daily doses of ciprofloxacin were designed to provide 8-fold ranges of the ratio of area under the concentration-time curve (AUC) to the MIC, 58-466 and 116-932 (mg x h/L)/(mg/L), respectively. The antimicrobial effect was expressed by its intensity: the area between the control growth in the absence of antibiotics and the antibiotic-induced time-kill/regrowth curves (I(E)). Linear relationships established between I(E) and log AUC/MIC were bacterial strain-independent but specific for the quinolones (r2 = 0.99 in both cases). At a given AUC/MIC ratio, the I(E)s of trovafloxacin were greater than those of ciprofloxacin, suggesting that the antimicrobial effect of trovafloxacin compared with ciprofloxacin against staphylococci may be even greater than might be expected from the difference in their MICs. These data were combined with previous results obtained with three Gram-negative bacteria. Again, I(E) correlated well with the log AUC/MIC of trovafloxacin and ciprofloxacin in a strain- and species-independent fashion (r2 = 0.94 and 0.96, respectively). On this basis, a value of the AUC/MIC of trovafloxacin which might be equivalent to Schentag's AUC/MIC = 125 (mg x h/L)/(mg/L) reported as the breakpoint value for ciprofloxacin was estimated at 71 (mg x h/L)/(mg/L) with the respective MIC breakpoint of 0.27 mg/L. Based on the I(E)-log AUC/MIC relationships, the I(E)s were plotted against the logarithm of trovafloxacin and ciprofloxacin dose (D) for hypothetical representatives of S. aureus, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa with MICs corresponding to the MIC50s. These I(E)-log D relationships allow prediction of the effect of a given quinolone on a representative strain of the bacterial species.
为比较曲伐沙星和环丙沙星的药效学,选取三株对不同最低抑菌浓度(MIC)(分别为0.03、0.15、0.6mg/L和0.1、0.25、1.25mg/L)的金黄色葡萄球菌临床分离株,根据它们各自9.25小时和4小时的半衰期,使其暴露于浓度逐渐降低的喹诺酮类药物中。对于每种菌株,设计单剂量的曲伐沙星和每日两次剂量的环丙沙星,以分别提供浓度-时间曲线下面积(AUC)与MIC之比的8倍范围,即分别为58 - 466和116 - 932(mg·h/L)/(mg/L)。抗菌效果通过其强度来表示:即无抗生素时的对照生长曲线与抗生素诱导的时间-杀菌/再生长曲线之间的面积(I(E))。I(E)与log AUC/MIC之间建立的线性关系不依赖于细菌菌株,但对喹诺酮类药物具有特异性(两种情况下r2均为0.99)。在给定的AUC/MIC比值下,曲伐沙星的I(E)大于环丙沙星,这表明与环丙沙星相比,曲伐沙星对葡萄球菌的抗菌效果可能比根据其MIC差异预期的还要大。这些数据与先前对三种革兰氏阴性菌获得的结果相结合。同样,I(E)与曲伐沙星和环丙沙星的log AUC/MIC以不依赖于菌株和菌种的方式具有良好的相关性(r2分别为0.94和0.96)。在此基础上,估计曲伐沙星的AUC/MIC值可能相当于Schentag报道的环丙沙星的AUC/MIC = 125(mg·h/L)/(mg/L)的断点值,为71(mg·h/L)/(mg/L),相应的MIC断点为0.27mg/L。基于I(E)-log AUC/MIC关系,针对金黄色葡萄球菌、大肠杆菌、肺炎克雷伯菌和铜绿假单胞菌的具有对应MIC50的假设代表性菌株,将I(E)与曲伐沙星和环丙沙星剂量(D)的对数作图。这些I(E)-log D关系允许预测给定喹诺酮类药物对该细菌菌种代表性菌株的作用。